Kolexia
Lebon Delphine Hématologie
Lebon Delphine
Hématologie
Centre Hospitalier D'Amiens Salouël Site Sud
Salouël, France
107 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Maladie résiduelle Maladie du greffon contre l'hôte Myélome multiple Maladie aigüe Maladie veno-occlusive hépatique Leucémie aiguë promyélocytaire

Collaborateurs

Voir plus
Marolleau Jean Pierre
Marolleau Jean Pierre
Centre Hospitalier D'Amiens Salouël Site Sud, Salouël, France
Berthon Céline
Berthon Céline
Hôpital Huriez, Lille, France
Preudhomme Claude
Preudhomme Claude
Hôpital Albert Calmette, Lille, France
Duployez Nicolas
Duployez Nicolas
Hôpital Albert Calmette, Lille, France

Industries

Voir plus
BMS
4 collaboration(s)
Dernière en 2023
Pfizer
3 collaboration(s)
Dernière en 2021
Novartis
2 collaboration(s)
Dernière en 2021
Parexel
1 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Essai Clinique (Syros Pharmaceuticals)   11 mars 2024
National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup
Essai Clinique (Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH)   22 février 2024
PIEZO1 is essential for the survival and proliferation of acute myeloid leukemia cells.
Cancer medicine   14 février 2024
OGILAR: Open-label, Phase 2 Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
Essai Clinique (French Innovative Leukemia Organisation)   05 février 2024
ALFA2101: An ALFA 2101 Multicenter Randomized Phase II Study: CPX-351 Versus Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
Essai Clinique (CHU Nice)   29 janvier 2024
STIM2 is involved in the regulation of apoptosis and the cell cycle in normal and malignant monocytic cells.
Molecular oncology   17 janvier 2024
AVENHIR: Phase II Study With Safety run-in of Azacitidine (AZA) Combined With Venetoclax (VEN) in Patients With Higher-risk Chronic Myelomonocytic Leukemia (CMML)
Essai Clinique (Abbvie)   02 janvier 2024
Impressive extramedullary plasmacytoma response in refractory multiple myeloma treated with teclistamab.
EJHaem   23 novembre 2023
AGORA-1 /ALFA 2100 Study : A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD Relapse/Refractory (R/R) AML
Essai Clinique (Centre Antoine Lacassagne)   09 novembre 2023
Atgam Efficacy and Safety in Moderate-to-Very Severe Acquired Aplastic Anemia: Outcome of a Large Multicenter Cohort of 634 Children and Adults from the French Authorization for Temporary Use Surveillance Program
65th ASH Annual Meeting Abstracts   02 novembre 2023